ショートコース

8月7日(水) | 6:30-9:30 pm

チェックポイント免疫療法およびその他のがん免疫療法のリード化合物に対応するバイオアッセイの開発

Instructor: Sofie Pattijn, CTO, ImmunXperts

About This course:

During the last few years, significant advancement has been made in the clinical application of cancer immunotherapies. Molecules directed against immune checkpoints and other agonists show great promise for treatment of a variety of malignancies. Early evaluation of the effectiveness of candidate therapeutics and combination therapies can be done using in vitro bioassays with primary mouse or human immune cells. These can be used to evaluate the functionality of check-point blockers, the effect of molecules on macrophages and myeloid derived suppressor cells and regulatory T cells.

TOPICS TO BE COVERED INCLUDE:

  • Developing a functional bioassay from scratch
  • Handling primary immune cells
  • What do the data tell us?
  • Challenges and pitfalls
  • Examples and case studies

Sofie Pattijn (CTO and founder, ImmunXperts) has over 20 years of experience in the field of immunogenicity assessment (vaccines and biotherapeutics) and in vitro assay development. She has extensive hands-on lab experience and has managed and coached several In Vitro teams over the last decade. From 2008 till 2013 she was Head of the In Vitro Immunogenicity group at AlgoNomics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics, Belgium for over 15 years.

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English


更新履歴
2019/07/23
講演者・スポンサー更新
2019/07/09
スポンサー更新
2019/06/20
スポンサー更新
2019/05/17
アジェンダ・スポンサー更新
2019/04/10
アジェンダ更新
2019/04/09
アジェンダ・スポンサー更新
2019/03/28
スポンサー更新




メール配信サービス